New long-term results from the pivotal EMBARK trial indicate ELEVIDYS, Sarepta's gene therapy, continues to alter the disease trajectory for boys with Duchenne muscular dystrophy, with no new safety concerns emerging over three years.
Following the FDA's decision to remove the clinical hold on Intellia's Nex-Z hATTR-PN trial, analysts at Baird and H.C. Wainwright have significantly raised their price targets for the CRISPR gene-editing pioneer, citing reduced regulatory risk and a clearer path forward.
Pharmaceutical giant Eli Lilly announces a major $3.5 billion manufacturing expansion for its weight-loss drugs and enters two strategic research collaborations in gene editing and immunology, signaling aggressive growth plans amid a recent stock valuation dip.
Sanofi announces promising late-stage results for its immunology candidate amlitelimab and expands into genetic therapies via an investment in Sensorion, signaling a strategic push into high-value therapeutic areas.
Eli Lilly bolsters its long-term growth strategy through two new R&D partnerships and a key regulatory milestone for an ovarian cancer drug, signaling a strategic push beyond its blockbuster diabetes and obesity treatments.
Cogent Biosciences secures a key FDA Breakthrough Therapy Designation for its bezuclastinib-sunitinib combination in advanced GIST, following promising Phase 3 data that showed a halving of disease progression risk.
Regeneron Pharmaceuticals is positioning its experimental obesity drug, olatorepatide, as a potential game-changer by combining significant weight loss with a dramatic reduction in 'bad' cholesterol. The company believes this dual benefit could carve out a unique niche in the competitive $150 billion market, currently led by Novo Nordisk and Eli Lilly.
Amid a quarter dominated by mega-cap tech and AI fervor, Pzena Investment Management's value-focused fund highlighted discount retailer Dollar General as a key performer, driven by strong earnings that propelled its stock.
A sharp 16% weekly decline in enGene Holdings' share price puts significant pressure on its largest shareholder group—private equity firms controlling nearly half the company—raising questions about strategy and future direction amid broader market volatility.
While robust cash generation is a hallmark of financial health, it doesn't guarantee stock outperformance. We examine three companies—PVH, Scorpio Tankers, and Amneal Pharmaceuticals—where strong cash flows are overshadowed by strategic challenges, raising red flags for discerning investors.
Takeda Pharmaceutical raises its FY2025 revenue and profit guidance following resilient nine-month results and announces U.S. availability of a new ready-to-use immunoglobulin therapy for primary immunodeficiency, fueling discussions on its growth strategy amid high debt and margin pressures.
Generac Holdings' shares have surged 19% in a month, reigniting the debate over its valuation. While recent momentum is strong, a five-year decline of 38% underscores the challenges. Analysts see a potential upside, but risks from the residential solar slowdown and data center demand volatility loom.
While robust cash generation is a hallmark of a healthy business, it doesn't automatically translate to a sound investment. We examine three companies with strong free cash flow margins where valuation and strategic concerns give investors pause.
A Florida couple is suing their fertility clinic after discovering the baby girl born via IVF is not genetically related to them, sparking a complex legal and ethical battle over parentage and clinic accountability.
Novo Nordisk charts a bold new course, launching a pivotal oral obesity drug while restructuring its workforce and deepening its investment in next-generation cell therapies for metabolic diseases.
Chinese autonomous driving leader WeRide has launched its proprietary general-purpose simulation model, Genesis, designed to bridge the gap between real-world data and virtual testing. The platform promises to drastically cut development time and costs for AV systems, from advanced driver-assistance features to fully autonomous robotaxis.
Regeneron Pharmaceuticals reported a steady finish to 2025, driven by growth in key drugs Dupixent and EYLEA HD. While navigating competitive pressures on its legacy blockbuster, the biotech giant outlined an ambitious 2026 strategy focused on regulatory milestones and a broad clinical pipeline.
A new Fox News survey reveals Democrats leading Republicans 52% to 46% in a generic congressional ballot for the 2026 midterms, the highest level of support recorded for either party in this poll series. Voter priorities and sharp partisan divides on key issues shape the early political landscape.
Cathay General Bancorp announces the retirement of long-time CFO Heng W. Chen after two decades, appointing Albert J. Wang as his successor. The leadership change at the $50.69-per-share regional bank comes amid a strong multi-year stock performance and focuses investor attention on continuity in financial strategy.
General Dynamics secures a major multi-year U.S. Navy contract for systems modernization, reinforcing its pivotal role in naval defense and underscoring the strength of its record order backlog amid robust segment performance.
